00512 GRANDPHARMA
- 4.320
- +0.060+1.41%
GRANDPHARMA News
GRANDPHARMA: Notice of availability to Registered Shareholders and Reply Form
GRANDPHARMA: Notice of availability to Non-registered Shareholders and Reply Form
GRANDPHARMA: ESG Report 2023
GRANDPHARMA: Proxy form for the annual general meeting to be held on Tuesday, 4 June 2024 or any adjournment thereof
GRANDPHARMA: Notice of Annual General Meeting
GRANDPHARMA: (1) GENERAL MANDATE TO REPURCHASE SHARES AND ISSUE NEW SHARES; (2) RE-ELECTION OF RETIRING DIRECTORS AND CONTINUOUS APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR SERVING MORE THAN NINE YEARS; AND (3) NOTICE OF ANNUAL GENERAL MEETING
GRANDPHARMA: Annual Report 2023
GRANDPHARMA: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2024
GRANDPHARMA: VOLUNTARY ANNOUNCEMENT: THE GROUP INTRODUCES A GLOBAL INNOVATIVE PRODUCT FOR THE TREATMENT OF DEMODEX BLEPHARITIS AND MEIBOMIAN GLAND DISEASE WITH DEMODEX MITES
GRANDPHARMA: Final dividend for the year ended 31 December 2023
GRANDPHARMA: Final dividend for the year ended 31 December 2023
GRANDPHARMA: THE GLOBAL INNOVATIVE RDC DRUG OF THE GROUP ITM-11 IS APPROVED TO CONDUCT PHASE III CLINICAL STUDY IN CHINA
GRANDPHARMA: Final dividend for the year ended 31 December 2023
GRANDPHARMA: Clarification Announcement in relation to Closure of Register of Members
GRANDPHARMA: Final dividend for the year ended 31 December 2023
GRANDPHARMA: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
GRANDPHARMA: DATE OF BOARD MEETING
GRANDPHARMA: VOLUNTARY ANNOUNCEMENT: THE GROUPS GLOBAL INNOVATIVE OPHTHALMIC DRUG GPN00884 WAS APPROVED TO CONDUCT PHASE I CLINICAL STUDY IN CHINA
GRANDPHARMA: VOLUNTARY ANNOUNCEMENT: THE NDA OF A GLOBAL INNOVATIVE HORMONE NANOSUSPENSION EYE DROPS WAS APPROVED BY THE FDA
GRANDPHARMA: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 29 FEBRUARY 2024
Analysis
Price Target
No Data
